bioAffinity Technologies Inc. (BIAF) News
Filter BIAF News Items
BIAF News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
BIAF News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest BIAF News From Around the Web
Below are the latest news stories about BIOAFFINITY TECHNOLOGIES INC that investors may wish to consider to help them evaluate BIAF as an investment opportunity.
Enlivex Therapeutics and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TVORLANDO, FL / ACCESSWIRE / January 10, 2025 / RedChip Companies will air interviews with Enlivex Therapeutics Ltd. (Nasdaq:ENLV) and bioAffinity Technologies, Inc. (Nasdaq:BIAF) on the RedChip Small Stocks, Big Money™ show, a sponsored program on ... |
bioAffinity Technologies Boosts Sales with CyPath LungbioAffinity Technologies, Inc. ( (BIAF) ) just unveiled an update. bioAffinity Technologies, Inc. reports a successful year in 2024, significantly boosting sales and operations through its lung cancer detection product, CyPath Lung. The company plans to expand its market presence in 2025, leveraging its growth in the U.S. healthcare system and focusing on key regions and markets, including the VA and military sectors, to further increase the accessibility and adoption of its test. More about bio |
Join bioAffinity Technologies’ Exclusive Live Investor Webinar and Q&A Session on Thursday, December 19SAN ANTONIO, December 17, 2024--bioAffinity Technologies President and CEO Maria Zannes will be featured on RedChip Companies' investor webinar on Thursday, Dec. 19. |
bioAffinity Technologies Set for Continued Expansion in 2025SAN ANTONIO, December 12, 2024--bioAffinity reports successful execution of its pilot marketing program and steady growth in sales of the CyPath® Lung test in 2024. |
Veterans’ Research Foundation Spotlights CyPath® Lung’s Addition to the Federal Supply ScheduleSAN ANTONIO, December 05, 2024--NAVREF hosts a joint presentation by bioAffinity and Federal Supply System officials about adding CyPath® Lung to the VA healthcare system. |
bioAffinity Technologies Reports $2.4 Million Revenue for Q3 2024SAN ANTONIO, November 14, 2024--bioAffinity Technologies releases financial results for the three months ended September 30, 2024. |
bioAffinity Technologies Appoints New Chief Science Officer to Spearhead Product DevelopmentSAN ANTONIO, November 04, 2024--bioAffinity Technologies promotes Senior VP William Bauta, Ph.D., to Chief Science Officer to spearhead product development. |
bioAffinity Technologies Announces Award of Japanese Patent for CyPath® LungSAN ANTONIO, October 30, 2024--bioAffinity Technologies receives a Japanese patent for the method behind the CyPath® Lung diagnostic test for early-stage lung cancer. |
WallachBeth Capital Announces Closing of bioAffinity Technologies $2.6 Million Registered Direct Offering & Concurrent Private PlacementWallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, has closed its previously announced registered direct offering with institutional investors for the purchase and sale of 2,048,294 shares (the "Shares") of common stock at a price of $1.30 per share and concurrent pri |
bioAffinity Technologies Announces Closing of $2.6 Million Registered Direct Offering & Concurrent Private PlacementSAN ANTONIO, October 21, 2024--bioAffinity Technologies announces closing of $2.6 million registered direct offering and concurrent private placement |